RFG Advisory’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-8,493
| Closed | -$784K | – | 746 |
|
|
2024
Q2 | $784K | Buy |
8,493
+709
| +9% | +$65.5K | 0.03% | 399 |
|
|
2024
Q1 | $744K | Buy |
7,784
+521
| +7% | +$49.8K | 0.03% | 407 |
|
|
2023
Q4 | $554K | Buy |
+7,263
| New | +$554K | 0.02% | 427 |
|
|
2023
Q3 | – | Sell |
-5,425
| Closed | -$512K | – | 639 |
|
|
2023
Q2 | $512K | Sell |
5,425
-83
| -2% | -$7.83K | 0.02% | 414 |
|
|
2023
Q1 | $456K | Buy |
5,508
+109
| +2% | +$9.02K | 0.02% | 433 |
|
|
2022
Q4 | $443K | Buy |
5,399
+259
| +5% | +$21.3K | 0.02% | 435 |
|
|
2022
Q3 | $358K | Buy |
5,140
+171
| +3% | +$11.9K | 0.02% | 447 |
|
|
2022
Q2 | $527K | Buy |
4,969
+255
| +5% | +$27K | 0.03% | 345 |
|
|
2022
Q1 | $555K | Buy |
4,714
+297
| +7% | +$35K | 0.04% | 297 |
|
|
2021
Q4 | $572K | Buy |
4,417
+138
| +3% | +$17.9K | 0.04% | 277 |
|
|
2021
Q3 | $484K | Sell |
4,279
-156
| -4% | -$17.6K | 0.04% | 281 |
|
|
2021
Q2 | $459K | Sell |
4,435
-57
| -1% | -$5.9K | 0.04% | 282 |
|
|
2021
Q1 | $376K | Buy |
4,492
+244
| +6% | +$20.4K | 0.04% | 296 |
|
|
2020
Q4 | $385K | Buy |
4,248
+567
| +15% | +$51.4K | 0.05% | 282 |
|
|
2020
Q3 | $294K | Buy |
3,681
+332
| +10% | +$26.5K | 0.04% | 317 |
|
|
2020
Q2 | $231K | Buy |
+3,349
| New | +$231K | 0.04% | 338 |
|
|
2020
Q1 | – | Sell |
-3,033
| Closed | -$236K | – | 370 |
|
|
2019
Q4 | $236K | Buy |
+3,033
| New | +$236K | 0.04% | 323 |
|